Boxer Capital’s Cytokinetics CYTK Stock Holding History

Boxer Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,100,000	Closed	-$111M	–	11
2024 Q3	$111M	Hold	2,100,000	–	–	5.44%	5
2024 Q2	$114M	Hold	2,100,000	–	–	5.99%	3
2024 Q1	$147M	Hold	2,100,000	–	–	7.27%	2
2023 Q4	$175M	Hold	2,100,000	–	–	8.74%	2
2023 Q3	$61.9M	Hold	2,100,000	–	–	3.29%	10
2023 Q2	$68.5M	Hold	2,100,000	–	–	3.18%	10
2023 Q1	$73.9M	Hold	2,100,000	–	–	3.63%	10
2022 Q4	$96.2M	Hold	2,100,000	–	–	5.07%	3
2022 Q3	$102M	Hold	2,100,000	–	–	5.72%	2
2022 Q2	$82.5M	Hold	2,100,000	–	–	5.23%	2
2022 Q1	$77.3M	Hold	2,100,000	–	–	3.97%	7
2021 Q4	$95.7M	Hold	2,100,000	–	–	3.72%	6
2021 Q3	$75.1M	Hold	2,100,000	–	–	2.62%	8
2021 Q2	$41.6M	Hold	2,100,000	–	–	1.47%	16
2021 Q1	$48.8M	Hold	2,100,000	–	–	1.66%	15
2020 Q4	$43.6M	Buy	+2,100,000	New	+$38.4M	1.4%	20

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital's CYTK Position: Q4 2024 in Review

Boxer Capital sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 2,100,000 shares — an estimated $111M sold.

Boxer Capital first reported a position in CYTK in Q4 2020 and held it in 16 quarters. The position peaked at $175M in Q4 2023. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

Boxer Capital reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 2,100,000 Cytokinetics shares in Q4 2024, an estimated $111M.
Boxer Capital first reported a position in Cytokinetics in Q4 2020 and held it in 16 quarters.
Boxer Capital's Cytokinetics position peaked at $175M in Q4 2023.
346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.